CN102526343B - Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals - Google Patents

Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals Download PDF

Info

Publication number
CN102526343B
CN102526343B CN 201210027793 CN201210027793A CN102526343B CN 102526343 B CN102526343 B CN 102526343B CN 201210027793 CN201210027793 CN 201210027793 CN 201210027793 A CN201210027793 A CN 201210027793A CN 102526343 B CN102526343 B CN 102526343B
Authority
CN
China
Prior art keywords
blood
chinese medicine
medicine composition
fructus
traditional chinese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 201210027793
Other languages
Chinese (zh)
Other versions
CN102526343A (en
Inventor
谭曜
单伟光
马中春
龙再浩
王群威
肖鹏
谭映
Original Assignee
谭曜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 谭曜 filed Critical 谭曜
Priority to CN 201210027793 priority Critical patent/CN102526343B/en
Publication of CN102526343A publication Critical patent/CN102526343A/en
Application granted granted Critical
Publication of CN102526343B publication Critical patent/CN102526343B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention relates to a traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals. The traditional Chinese medicine composition is prepared from the following ingredients in parts by weight: 15 to 30 of astragalus mongholicus, 10 to 15 of fructus rosae laevigatae, 10 to 15 of suberect spatholobus stem, 5 to 10 of lucid ganoderma, 10 to 15 of uncooked hawthorn, 5 to 10 of angelica sinensis, 10 to 15 of alvia miltiorrhiza, 5 to 10 of pawpaw, 10 to 20 of kudzuvine root, 15 to 30 of parasitic loranthus, 10 to 15 of Chinese wolfberry fruit and 10 to 20of Chinese data. Compared with the prior art, the traditional Chinese medicine composition has the advantages that the qi and the blood of the whole body are dredged, the qi and blood regulation effect is realized, and good curative effects are realized on the helping in aspects of prompting the paralyzed limb and body movement, balancing the coordination function and the like.

Description

Inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition
Technical field
The present invention relates to a kind of inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition that can be applied to the apoplexy treatment.
Background technology
Apoplexy be faint suddenly, unconsciousness, thirsty, speech is not smoothgoing, hemiplegia is primary symptom a kind of disease.It comprises the disease such as cerebral hemorrhage, cerebral thrombosis, cerebral embolism, transient ischemic attack of modern medicine, is a kind of mortality rate disease with high.The age of onset of primary disease also tends to rejuvenation, is to threaten human life and the great illness of quality of life.It often leaves sequela shapes such as not smoothgoing puckery unfavorable, the crooked mouth and tongue of the different hemiplegia of degree, numbness, speech, dementia.At present, clinically based on the neutrality treatment, suitably give mannitol and dexamethasone, to reducing intracranial pressure, alleviate cerebral edema, eliminate free radical, increase cerebral tissue to the toleration of anoxia, promote the pathological changes cerebral tissue function to recover to have good action.But exist the deficiency that treatment cycle is long, effect is undesirable, common drug matching is mixed and disorderly, take effect slowly, and Western medicine can only temporaryly be alleviated, and cures the symptoms, not the disease, and the expense costliness.
The traditional Chinese medical science is thought: apoplexy is the card of deficiency in origin and excess in superficiality, is preponderance of either YIN or YANG at this, and mechanism of qi is disorderly contrary; Be designated as fire and wind stirring up each other, expectorant is turbid to be jammed blood-stasis internal-depression.The common cause of disease has is worried angryly, and on the scoop, or addiction to greasy and sweet foods, it is tired to indulge in sensual pleasures, or daily life is careless etc.After the apoplexy, internal organs are deficient, functional disorder, and with the passing of time pathogenic factor is delaied, and healthy energy must be consumed surely, and is more obvious with this deficient syndrome, wherein especially gives prominence to the deficiency of vital energy, the hepatic and renal YIN deficiency, heart deficiency of spleen-YANG.Therefore, the treatment apoplexy is when the method with the spleen invigorating of employing YIN nourishing, blood circulation promoting and blood stasis dispelling.
Blood circulation promoting and blood stasis dispelling is the method for dispeling blood stasis circulation blood vessels, has blood absorption, detumescence, antiinflammatory that the blood circulation of improvement, hemostasis, promotion overflow, improves effect such as neurotrophy.No matter hemorrhagic apoplexy, cerebral infarction, it is stagnant not smooth that its basic pathology of morbidity back is the brain arteries and veins stasis of blood, and blood circulation promoting and blood stasis dispelling can improve cerebral tissue blood vessel microcirculation, promotes the foundation of absorption of hematoma and side Zhi Xunhuan, favourable functional rehabilitation.Clinical practice for many years confirms: activating blood and removing stasis Method can be applied to the clinical treatment of hemorrhage suffering from acute stroke, and is with the therapeutic effect that can improve hemorrhagic apoplexy behind the drug for invigorating blood circulation and eliminating stasis to a certain extent.Control hemorrhagic apoplexy and the prognosis that improves hemorrhage apoplexy had important significance for theories and practical significance.In recent years, activating blood and removing stasis drug is further discovered, activating blood and removing stasis drug has dual regulation to clotting mechanism, hemorrhagic apoplexy is at acute attack stage, can't cause again hemorrhage and increase the weight of the state of an illness with drug for invigorating blood circulation and eliminating stasis, on the contrary, because blood stasis is dispeled, the unobstructed stopped bleeding that is conducive to of blood flow.After the cerebral hemorrhage morbidity, as long as the gas of superinverse is returned, the multiple smooth-going and superinverse (blood pressure stabilization and do not have crisis etc.) not of gas, there is no obvious bleeding tendency (not having obvious disturbances of blood coagulation etc.) and just can use activating blood and resolving stasis and treating immediately, with the elimination of promotion cerebral edema and the absorption of hematoma, improve brain blood circulation, promote side Zhi Xunhuan to set up, recover every function, improve curative effect.But for drug for invigorating blood circulation and eliminating stasis certain selectivity to be arranged at treatment cerebral thrombosis, cerebral embolism and hemorrhagic apoplexy.
Summary of the invention
Technical problem to be solved by this invention is that a kind of inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition that can be applied to the apoplexy treatment is provided at the above-mentioned state of the art.
The present invention solves the problems of the technologies described above the technical scheme that adopts: a kind of inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition, made by the raw material of following parts by weight:
The Radix Astragali 15~30, Fructus Rosae Laevigatae 10~15, Caulis Spatholobi 10~15, Ganoderma 5~10, Fructus Crataegi 10~15, Radix Angelicae Sinensis 5~10, Radix Salviae Miltiorrhizae 10~15, Fructus Chaenomelis 5~10, Radix Puerariae 10~20, Herba Taxilli 15~30, Fructus Lycii 10~15, Fructus Jujubae 10~20.Raw material is ground to form smalls to be made capsule or makes tablet or decoct according to a conventional method.
As the best: the raw material by following parts by weight is made:
The Radix Astragali 22, Fructus Rosae Laevigatae 13, Caulis Spatholobi 12, Ganoderma 8, Fructus Crataegi 12, Radix Angelicae Sinensis 8, Radix Salviae Miltiorrhizae 12, Fructus Chaenomelis 7, Radix Puerariae 15, Herba Taxilli 22, Fructus Lycii 8, Fructus Jujubae 15.
Pharmacology of the present invention is as follows:
The Radix Astragali: benefiting QI for activating blood circulation, enhance metabolism, microcirculation improvement reduces platelet adhesion rate, reduces thrombosis and removes free radical, lipoid peroxidization resistant.
Fructus Rosae Laevigatae, the polysaccharide of Fructus Rosae Laevigatae have fat and the antioxidation of pressing down, and athero in blood sugar lowering, triglyceride and minimizing liver and the mesentery is had good result.Hypercholesterolemia had tangible preventive and therapeutic action.
Caulis Spatholobi: having enriches blood invigorates blood circulation, the effect of relaxing muscles and tendons and activating QI and blood in the collateral.
Ganoderma: the QI invigorating tonify deficiency, blood fat-reducing blood pressure-decreasing, the anticoagulant effect improves the cardiovascular effect.
Fructus Crataegi contain in a large number can vessel softening material, thereby reduce the calmness of cholesterol in the organ, up to the effect of the fat of dispelling, heart tonifying, have the effect of promoting digestion and invigorating the stomach simultaneously.
Radix Angelicae Sinensis: anti-platelet aggregation and anti thrombotic action, and can promote hemoglobin and erythrocytic generation, and resist myocardial ischemia and the blood vessel dilating effect, can improve peripheral circulation.
Radix Salviae Miltiorrhizae: coronary artery dilating, increase myocardial flow, antithrombotic forms, and local congestion alleviates, blood circulation improves.
Fructus Chaenomelis has the effect of relaxing muscles and tendons and activating QI and blood in the collateral, has the effect of stomach function regulating removing dampness simultaneously.
Radix Puerariae has the brain of improvement blood circulation, improve coronary circulation and myocardial nutrition, arrhythmia, anticoagulant, blood pressure lowering, blood sugar lowering, cooling and analgesic, anti-inflammatory analgesic, lax intestinal smooth muscle, J3 one adrenoceptor retardation.
Herba Taxilli has blood pressure lowering, coronary artery dilator, and the blood flow of increase cardiovascular and cerebrovascular vessel has blood fat reducing and atherosclerosis and antithrombotic effect.
Fructus Lycii has the lipid of inhibition to deposit in hepatocyte and promotes hepatocyte new life. thereby the effect of anti-fatty liver and blood fat reducing, blood pressure lowering is arranged.Fructus Jujubae, invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind.
Compared with prior art, the invention has the advantages that: multi-flavor medicine reasonable compatibility, force action, in mediation whole body meridian QI and blood, QI and blood regulating has been received better curative effect in the recovery that promotes aspects such as paralyzed limbs motion, balance coordination function.Cephalophyma is absorbed as early as possible, and the blood vessel of obstruction is dredged as early as possible, improves cerebral blood circulation; the protection brain cell reduces cerebral edema, improves cerebral blood supply; and the damage that can alleviate brain, brain function is recovered gradually, the apoplectic hemiplegia patient there is certain therapeutical effect.
The specific embodiment
Describe in further detail below in conjunction with the present invention of embodiment.
Embodiment 1: present embodiment is preferred embodiment, and inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition is made by the raw material of following parts by weight: Radix Astragali 22g, Fructus Rosae Laevigatae 13g, Caulis Spatholobi 12g, Ganoderma 8g, Fructus Crataegi 12g, Radix Angelicae Sinensis 8g, Radix Salviae Miltiorrhizae 12g, Fructus Chaenomelis 7g, Radix Puerariae 15g, Herba Taxilli 22g, Fructus Lycii 8g, Fructus Jujubae 15g.
With being decocted in water for oral dose: above-mentioned 12 flavor Chinese medicines are put into marmite, and first fries in shallow oil and adds water 600ml and soaked 30 minutes, after boiling with high heat earlier, and 30 minutes at a simmer of reuse, the about 350ml of taking liquid; Second fries in shallow oil and adds water 500ml, boils earlier the back reuse with high heat 25 minutes at a simmer, the about 350ml of taking liquid; Two boil medicine liquid mix after clothes at twice, morning and evening service once, decoction being taken warmly.1 dose of every day, decocting 2 times.Sooner or later 1h obeys after meal.
92 routine patients: be in hospital 32 cases and outpatient service 60 cases, male 48 people wherein, women 44 people, the oldest 84 years old, minimum 39 years old, average 59 years old; Cerebral infarction 52 examples, cerebral hemorrhage 29 examples, cerebral thrombosis 11 examples; The right avertence paralysis is main 61 examples, left avertence paralysis 31 examples; The shortest person of the course of disease 6 months, elder 2 years 6 months, average course of disease 8 months.1 dose/d, 10 doses was 1 course for the treatment of, and rest 2d carries out next course for the treatment of, treats 3 courses for the treatment of altogether.
" apoplexy diagnosis and efficacy assessment standard " (try) that criterion of therapeutical effect is drafted formulation according to State Administration of Traditional Chinese Medicine's encephalopathy emergency case scientific research cooperative groups in 1996 carries out clinical efficacy evaluation.Recovery from illness: lamprophonia, the Ipsilateral muscular strength reaches the V level, and the upper and lower extremities function is recovered normally fully, and life can be taken care of oneself; Produce effects: it is unfavorable that language has slightly, and the Ipsilateral muscular strength reaches the IV level, and the upper and lower extremities function is obviously progressive, but still has paresis; Take a turn for the better: language makes moderate progress, and the Ipsilateral lower-limb muscular strength reaches the IV level, and the upper limb muscular strength reaches the III level, and function only has part to recover; Invalid: treat 3 courses for the treatment of, symptom and sign does not have improvement.Therapeutic outcome: 56 examples that are almost recovered, produce effects 16 examples, effective 16 examples, invalid 4 examples, total effective rate is 95.65%.
Embodiment 2:, the inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition in the present embodiment is made up of following component and weight proportion thereof: Radix Astragali 15g, Fructus Rosae Laevigatae 15g, Caulis Spatholobi 15g, Ganoderma 10g, Fructus Crataegi 10g, Radix Angelicae Sinensis 10g, Radix Salviae Miltiorrhizae 15g, Fructus Chaenomelis 10g, Radix Puerariae 20g, Herba Taxilli 15g, Fructus Lycii 15g, Fructus Jujubae 20g.
Embodiment 3: the inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition in the present embodiment is made up of following component and weight proportion thereof: Radix Astragali 30g, Fructus Rosae Laevigatae 10g, Caulis Spatholobi 10g, Ganoderma 5g, Fructus Crataegi 15g, Radix Angelicae Sinensis 5g, Radix Salviae Miltiorrhizae 10g, Fructus Chaenomelis 5g, Radix Puerariae 10g, Herba Taxilli 30g, Fructus Lycii 10g, Fructus Jujubae 10g.

Claims (1)

1. inrigorating qi and promoting blood circulation collateral dredging Chinese medicine composition, made by the raw material of following parts by weight:
The Radix Astragali 22, Fructus Rosae Laevigatae 13, Caulis Spatholobi 12, Ganoderma 8, Fructus Crataegi 12, Radix Angelicae Sinensis 8, Radix Salviae Miltiorrhizae 12, Fructus Chaenomelis 7, Radix Puerariae 15, Herba Taxilli 22, Fructus Lycii 8, Fructus Jujubae 15.
CN 201210027793 2012-02-09 2012-02-09 Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals Expired - Fee Related CN102526343B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201210027793 CN102526343B (en) 2012-02-09 2012-02-09 Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201210027793 CN102526343B (en) 2012-02-09 2012-02-09 Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals

Publications (2)

Publication Number Publication Date
CN102526343A CN102526343A (en) 2012-07-04
CN102526343B true CN102526343B (en) 2013-09-11

Family

ID=46335163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201210027793 Expired - Fee Related CN102526343B (en) 2012-02-09 2012-02-09 Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals

Country Status (1)

Country Link
CN (1) CN102526343B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104474205A (en) * 2014-12-05 2015-04-01 郭民召 Oral liquor for reinforcing qi, activating blood circulation and dredging collaterals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185007C (en) * 2003-12-08 2005-01-19 张小朋 Blood-lipid-reducing thrombolytic medicine
CN101347528A (en) * 2008-08-29 2009-01-21 谭镒昌 Chinese medicinal composition for resisting cardiovascular and cerebrovascular diseases
CN101589810A (en) * 2009-04-30 2009-12-02 刘学杰 Geshen health care wine and production method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100022128A (en) * 2008-08-13 2010-03-02 (주)한중보건연구원 Bow band function
LT2411028T (en) * 2009-03-27 2019-08-26 Moleac Pte Ltd. Therapy for promoting cell growth
KR101078306B1 (en) * 2009-04-17 2011-10-31 (주)에이치케이바이오텍 Fibrinolytic Composition Having Culture Of Bacillus Subtilis Natto And Mushroom Fungi
JP5578646B2 (en) * 2009-06-19 2014-08-27 株式会社和漢生薬研究所 Orally administered composition for pharyngitis and influenza prevention / treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185007C (en) * 2003-12-08 2005-01-19 张小朋 Blood-lipid-reducing thrombolytic medicine
CN101347528A (en) * 2008-08-29 2009-01-21 谭镒昌 Chinese medicinal composition for resisting cardiovascular and cerebrovascular diseases
CN101589810A (en) * 2009-04-30 2009-12-02 刘学杰 Geshen health care wine and production method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JP特开2011-1321A 2011.01.06

Also Published As

Publication number Publication date
CN102526343A (en) 2012-07-04

Similar Documents

Publication Publication Date Title
CN101991816B (en) Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases
CN101254272B (en) Medicament for promoting coronary circulation and embolism resistance
CN102772704B (en) Medicament for treating geriatric disease
CN103211930B (en) Traditional Chinese preparation for reducing blood fat and blood pressure
CN105169214A (en) Traditional Chinese medicine composition for treating atherosclerosis, and preparation method thereof
CN103520366B (en) Be used for the treatment of the Chinese medicine of spastic hemiplegia after stroke
CN102198228A (en) Chinese medicinal preparation for treating hypertension
CN102512552B (en) Traditional Chinese medicine composition for treating exogenous fever
CN102441154B (en) A kind of Chinese medicine preparation for the treatment of gout
CN103610936B (en) A kind of Chinese medicine preparation and preparation method for the treatment of coronary heart disease
CN102526343B (en) Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals
CN102430105A (en) Traditional Chinese medicine composite for treating chronic gastritis
CN102266481B (en) Chinese medicinal preparation for treating chronic cerebral circulation insufficiency
CN102406743A (en) Traditional Chinese preparation for treating cerebral thrombosis
CN102397391A (en) Drug for treating hypertension, hyperlipaemia and blood hyperviscosity and preparation method thereof
CN102614459B (en) Traditional Chinese medicine spray for rapidly curing myocardial ischemia and preparation method thereof
CN103028094A (en) Chinese patent medicine for treating coronary heart disease
CN102614461A (en) Spray for rapidly relieving stenocardia and preparation method thereof
CN101244209B (en) Medicament for preventing or treating cardiovascular and cerebrovascular diseases
CN105477171A (en) Capsule used for treating hyperlipemia and preparation method of capsule
CN103655917B (en) A kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease
CN104173728A (en) Traditional Chinese medicine capsule for treating hyperglycemia
CN102631643B (en) Traditional Chinese medicine for treating atherosclerosis and preparation method of traditional Chinese medicine
CN103272080A (en) Medicine for treating waist pain caused by vein and blood disharmony
CN102755520A (en) Chinese medicinal preparation for treating cardiovascular disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130911

Termination date: 20160209

CF01 Termination of patent right due to non-payment of annual fee